NCT06578585

A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Interventional, Randomized, Double-blind, Placebo-controlled Trial Investigating the Safety and Tolerability of Lu AG09222 When Coadministered With Ubrogepant in Participants With Migraine

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant. This includes looking for any new or worsening medical issues the participants have with the treatment. During the trial, participants with migraine will receive ubrogepant oral tablets and an injection of either Lu AG09222 or a placebo.

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Ubrogepant	Tablet
DRUG	Lu AG09222	Solution for injection/infusion
DRUG	Placebo	Solution for injection/infusion

Timeline

• Start date: 2024-09-13
• Primary completion: 2025-07-11
• Completion: 2025-07-11
• First posted: 2024-08-29
• Last updated: 2025-10-14

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study